## 1 Introduction  
Historically, fibrin adhesives were used in oral and maxillofacial surgery for hemostasis after dental extraction in patients with clotting disorders, neural anastomoses, and skin grafts placement, in combination with the use of bone grafts for alveolar ridge augmentation and filling of bony cavities following cyst removal [1]. In 1994, [PERSON] published the first report on the use of autologous non-translational hemocomponents in oral and maxillofacial surgery [2]. An autologous fibrin adhesive (AFA) was added to a cancellous bone graft during mandibular reconstruction, and the results demonstrated earlier radiographic bone consolidation compared to bone grafts without AFA [2].  
Platelet concentrate refers to an autologous concentration of human platelets obtained by centrifuging blood. This results in a high concentration of several protein growth factors secreted actively by platelets. The first use of autologous platelet concentrates(platelet-rich plasma (PRP)) in maxillofacial surgery was introduced by [PERSON] et al. in 1998, in which at least three growth factors (platelet-derived growth factor (PDGF), transforming growth factor beta 1 (TGF-\(\beta\)1), and transforming growth factor beta 2 (TGF-\(\beta\)2) were identified in PRP. Healing of bone grafts with the addition of these growth factors produce a quantifiably enhanced result, evidenced by higher radiographic maturation rate and greater bone density shown by histomorphometric analysis [3]. However, up to the present time, controversy surrounds the efficacy of PRP and its true role in osteoinduction [4; 5; 6].  
The PRP products are subdivided according to leukocyte and fibrin content as follows: pure PRP (P-PRP), also known as plasma rich in growth factors (PRGF) or leukocyte-poor PRP, such as Cell Separator PRP [7] or Anitua' PRGF [8]; leukocyte- and platelet-rich plasma (L-PRP), such as PCCS [9] or Ace PRP [10]; pure platelet-rich fibrin (P-PRF), such as Fibrinet PRFM [11]; and leukocyte- and platelet-rich fibrin (L-PRF), such as Choukroun's PRF [12]. The details of each platelet concentrate are described elsewhere [7; 8; 9; 10; 11; 12].  
Leucocyte- and platelet-rich fibrin (L-PRF) has been considered as the second generation of platelet concentrate, and it was developed by [PERSON] et al. in 2001 [12]. Unlike PRP, L-PRF does not dissolve and disintegrate quickly due to the elimination of the anticoagulants or gelling agents while centrifuging. In the absence of anticoagulants, platelet activation and fibrin polymerization are triggered immediately. The L-PRF membrane has been shown to slowly release a significant amount of three main growth factors, namely, the TGF\(\beta\)1, platelet-derived growth factor AB (PDGF-AB), vascular endothelial growth factor (VEGF), and an important coagulation matricellular glycoprotein (thrombospondin-1, TSP-1) during at least the first seven days [13] up to 28 days [5].  
Intricate interaction between cellular and molecular pathways during wound healing progresses to the early and late inflammation phases, proliferation and migration of cells, angiogenesis, granulation tissue formation, and (finally) matrix formation and remodeling following tissue injury [14]; the role of each growth factor has been described elsewhere [15; 16; 17].  
Necrosis of the jawbones is dreadful, and debilitating complications that may develop following radiotherapy in the head and neck region, resulting in osteoradionecrosis (ORN), or from the therapeutic use of antiresorptive and antiangiogenic medications, resulting in medication-related osteonecrosis of the jaw (MRONJ). There is no universally accepted consensus for the best treatment of these lesions as treatment outcomes are unpredictable.